Skip to main
ARGX
ARGX logo

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 39%
Buy 54%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Argenx achieved breakeven on operating profit in the third quarter of 2024, with expectations for continued improvement in operating margins as sales increase and R&D spending stabilizes, supported by significant growth in global product net sales, which reached $737 million in the fourth quarter of 2024, reflecting a 29% quarter-over-quarter and 97% year-over-year increase. The company's strong revenue growth is attributed to sustained demand for its lead product, Vyvgart, which exhibits profound efficacy and a favorable safety profile, solidifying its position as the first branded biologic for generalized myasthenia gravis (gMG). Furthermore, Argenx's commitment to innovation is underscored by its robust pipeline and strategic R&D investment, which targets future growth in various rare autoimmune diseases, with projected revenue from Vyvgart in gMG, CIDP, and ITP expected to reach $3.2 billion by 2025.

Bears say

Argenx has reported a year-over-year decrease in R&D expenses, which fell 3.0% to $297.2 million, slightly exceeding analysts' estimates but indicating potential financial challenges in maintaining innovation. The company faces substantial risks, including slower-than-expected sales growth for its lead product, Vyvgart, along with significant competitive pressure and the potential for setbacks in ongoing developmental programs. Additionally, any clinical or regulatory issues could adversely impact the stock price, and a historic precedent exists in the biopharmaceutical sector where companies, like BIIB, have experienced revenue decline due to competition and loss of exclusivity, raising concerns for Argenx's future financial performance.

argenx (ARGX) has been analyzed by 28 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 54% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 28 analysts, argenx (ARGX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $602.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $602.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.